HomeAboutRankingsData Sources
Β© 2026 GeneE
🧬
GeneE
25 sources retrieved Β· Most recent: April 2026 Β· Index updated 14 days ago
β“˜GeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
SLC12A3
solute carrier family 12 member 3
Chromosome 16 Β· 16q13
NCBI Gene: 6559Ensembl: ENSG00000070915.10HGNC: HGNC:10912UniProt: J3QSS1
168PubMed Papers
21Diseases
13Drugs
454Pathogenic Variants
FUNCTIONAL ROLE
Transporter
RESEARCH IMPACT
Variant-Rich
CLINICAL
FDA Approved TargetOMIM Disease Gene
DATA QUALITY
βœ“ Experimental GO Evidenceβœ“ Swiss-Prot Reviewed
extracellular exosomerenal sodium ion absorptionprotein serine/threonine kinase bindingplasma membraneGitelman syndromehypertensionnephrotic syndromechronic kidney disease
✦AI Summary

SLC12A3 encodes the thiazide-sensitive sodium-chloride cotransporter (NCC), which serves as a key mediator of electroneutral sodium and chloride reabsorption in the kidney's distal convoluted tubules 123. The transporter functions through cotransport of Na+ and Cl- ions, maintaining electrolyte homeostasis and blood pressure regulation. Mechanistically, mutations in SLC12A3 can affect NCC function through multiple pathways: class 2 mutations eliminate transport activity, class 3 mutations impair protein trafficking to the plasma membrane, and class 4 mutations affect regulation or ion affinity while maintaining membrane localization 3. Recent research has revealed an additional function where SLC12A3 acts as a receptor for IL-18, triggering metabolic reprogramming in intestinal macrophages by promoting sodium influx and activating the STING pathway, leading to fatty acid oxidation and immune tolerance 4. Disease-wise, SLC12A3 mutations cause Gitelman syndrome, an autosomal recessive salt-losing tubulopathy characterized by hypokalemic metabolic alkalosis, hypomagnesemia, and hypocalciuria 12. Over 500 mutations have been identified, with missense mutations comprising approximately 59-72% of cases in various populations 15. The Arg913Gln variant shows association with diabetic nephropathy in type 2 diabetes patients 6.

Sources cited
1
SLC12A3 encodes NCC transporter and mutations cause Gitelman syndrome with missense mutations comprising ~59% of cases
PMID: 21415153
2
Gitelman syndrome is caused by inactivating SLC12A3 mutations leading to salt-losing tubulopathy with characteristic electrolyte abnormalities
PMID: 28003083
3
NCC functions as thiazide-sensitive cotransporter and mutations affect function through different mechanisms (classes 2, 3, and 4)
PMID: 22009145
4
Missense mutations account for over 72% of SLC12A3 mutations in Chinese patients with Gitelman syndrome
PMID: 31398183
5
SLC12A3 acts as IL-18 receptor triggering metabolic reprogramming in intestinal macrophages via sodium influx and STING pathway activation
PMID: 38906145
6
Arg913Gln variation in SLC12A3 is associated with diabetic nephropathy in type 2 diabetes patients
PMID: 31660880
Disease Associationsβ“˜21
Gitelman syndromeOpen Targets
0.86Strong
hypertensionOpen Targets
0.66Moderate
nephrotic syndromeOpen Targets
0.62Moderate
chronic kidney diseaseOpen Targets
0.61Moderate
congestive heart failureOpen Targets
0.61Moderate
myocardial infarctionOpen Targets
0.60Moderate
cardiovascular diseaseOpen Targets
0.59Moderate
edemaOpen Targets
0.58Moderate
angina pectorisOpen Targets
0.58Moderate
preeclampsiaOpen Targets
0.57Moderate
essential hypertensionOpen Targets
0.57Moderate
glomerulonephritisOpen Targets
0.55Moderate
genetic disorderOpen Targets
0.54Moderate
strokeOpen Targets
0.54Moderate
Bartter syndromeOpen Targets
0.53Moderate
cirrhosis of liverOpen Targets
0.53Moderate
heart failureOpen Targets
0.50Moderate
diabetes mellitusOpen Targets
0.48Moderate
HypokalemiaOpen Targets
0.43Moderate
cardiac arrhythmiaOpen Targets
0.37Weak
Gitelman syndromeUniProt
Pathogenic Variants454
NM_001126108.2(SLC12A3):c.1444-2_1462dupPathogenic
Familial hypokalemia-hypomagnesemia
β˜…β˜…β˜†β˜†2026
NM_001126108.2(SLC12A3):c.434G>A (p.Arg145His)Pathogenic
Familial hypokalemia-hypomagnesemia|not provided|Inborn genetic diseases
β˜…β˜…β˜†β˜†2026β†’ Residue 145
NM_001126108.2(SLC12A3):c.1924C>G (p.Arg642Gly)Pathogenic
Familial hypokalemia-hypomagnesemia|not provided
β˜…β˜…β˜†β˜†2026β†’ Residue 642
NM_001126108.2(SLC12A3):c.248G>A (p.Arg83Gln)Pathogenic
Familial hypokalemia-hypomagnesemia|not provided
β˜…β˜…β˜†β˜†2026β†’ Residue 83
NM_001126108.2(SLC12A3):c.1844C>T (p.Ser615Leu)Pathogenic
not provided|Familial hypokalemia-hypomagnesemia
β˜…β˜…β˜†β˜†2026β†’ Residue 615
NM_001126108.2(SLC12A3):c.2856+1G>TPathogenic
not provided|Familial hypokalemia-hypomagnesemia|Familial hypokalemia-hypomagnesemia;Bartter syndrome|Renal tubulopathies
β˜…β˜…β˜†β˜†2026
NM_001126108.2(SLC12A3):c.602G>T (p.Gly201Val)Likely pathogenic
not provided|Familial hypokalemia-hypomagnesemia
β˜…β˜…β˜†β˜†2026β†’ Residue 201
NM_001126108.2(SLC12A3):c.2549T>C (p.Leu850Pro)Pathogenic
Familial hypokalemia-hypomagnesemia|not provided|Inborn genetic diseases|SLC12A3-related disorder|Renal tubulopathies
β˜…β˜…β˜†β˜†2026β†’ Residue 850
NM_001126108.2(SLC12A3):c.815T>C (p.Leu272Pro)Pathogenic
Familial hypokalemia-hypomagnesemia|not provided
β˜…β˜…β˜†β˜†2026β†’ Residue 272
NM_001126108.2(SLC12A3):c.539C>A (p.Thr180Lys)Pathogenic
not provided|Familial hypokalemia-hypomagnesemia
β˜…β˜…β˜†β˜†2026β†’ Residue 180
NM_001126108.2(SLC12A3):c.1388G>A (p.Gly463Glu)Likely pathogenic
not provided|Familial hypokalemia-hypomagnesemia
β˜…β˜…β˜†β˜†2026β†’ Residue 463
NM_001126108.2(SLC12A3):c.2850_2851del (p.Arg950fs)Pathogenic
not provided|Familial hypokalemia-hypomagnesemia
β˜…β˜…β˜†β˜†2026β†’ Residue 950
NM_001126108.2(SLC12A3):c.2954G>A (p.Cys985Tyr)Pathogenic
not provided|Familial hypokalemia-hypomagnesemia
β˜…β˜…β˜†β˜†2026β†’ Residue 985
NM_001126108.2(SLC12A3):c.1067C>T (p.Ala356Val)Pathogenic
Familial hypokalemia-hypomagnesemia|SLC12A3-related disorder
β˜…β˜…β˜†β˜†2026β†’ Residue 356
NM_001126108.2(SLC12A3):c.1180+2T>CPathogenic
not provided|Familial hypokalemia-hypomagnesemia
β˜…β˜…β˜†β˜†2026
NM_001126108.2(SLC12A3):c.595_596del (p.Lys199fs)Pathogenic
not provided|Familial hypokalemia-hypomagnesemia
β˜…β˜…β˜†β˜†2026β†’ Residue 199
NM_001126108.2(SLC12A3):c.1925+1G>APathogenic
Familial hypokalemia-hypomagnesemia|not provided
β˜…β˜…β˜†β˜†2026
NM_001126108.2(SLC12A3):c.3050C>T (p.Thr1017Ile)Pathogenic
not provided|Familial hypokalemia-hypomagnesemia
β˜…β˜…β˜†β˜†2026β†’ Residue 1017
NM_001126108.2(SLC12A3):c.1262G>A (p.Cys421Tyr)Pathogenic
not provided|Familial hypokalemia-hypomagnesemia|SLC12A3-related disorder
β˜…β˜…β˜†β˜†2026β†’ Residue 421
NM_001126108.2(SLC12A3):c.1315G>A (p.Gly439Ser)Pathogenic
not provided|Familial hypokalemia-hypomagnesemia|Familial hypokalemia-hypomagnesemia;Bartter syndrome|Familial aortopathy|SLC12A3-related disorder|Inborn genetic diseases
β˜…β˜…β˜†β˜†2026β†’ Residue 439
View on ClinVar β†—
Drug Targets13
BENDROFLUMETHIAZIDEApproved
Thiazide-sensitive sodium-chloride cotransporter inhibitor
hypertension
BENZTHIAZIDEApproved
Thiazide-sensitive sodium-chloride cotransporter inhibitor
hypertension
CHLOROTHIAZIDEApproved
Thiazide-sensitive sodium-chloride cotransporter inhibitor
glomerulonephritis
CHLORTHALIDONEApproved
Thiazide-sensitive sodium-chloride cotransporter inhibitor
preeclampsia
CYCLOTHIAZIDEApproved
Thiazide-sensitive sodium-chloride cotransporter inhibitor
cardiovascular disease
HYDROCHLOROTHIAZIDEApproved
Thiazide-sensitive sodium-chloride cotransporter inhibitor
hypertension
HYDROFLUMETHIAZIDEApproved
Thiazide-sensitive sodium-chloride cotransporter inhibitor
cardiovascular disease
INDAPAMIDEApproved
Thiazide-sensitive sodium-chloride cotransporter inhibitor
hypertension
METHYCLOTHIAZIDEApproved
Thiazide-sensitive sodium-chloride cotransporter inhibitor
cardiovascular disease
METOLAZONEApproved
Thiazide-sensitive sodium-chloride cotransporter inhibitor
congestive heart failure
POLYTHIAZIDEApproved
Thiazide-sensitive sodium-chloride cotransporter inhibitor
cardiovascular disease
QUINETHAZONEApproved
Thiazide-sensitive sodium-chloride cotransporter inhibitor
cardiovascular disease
TRICHLORMETHIAZIDEApproved
Thiazide-sensitive sodium-chloride cotransporter inhibitor
hypertension
Related Genes
BSNDProtein interaction100%KLHL3Protein interaction99%WNK1Protein interaction97%SCNN1AProtein interaction97%SCNN1BProtein interaction97%SCNN1GProtein interaction97%
Tissue Expression6 tissues
Bone Marrow
100%
Ovary
17%
Lung
13%
Brain
7%
Liver
4%
Heart
0%
Gene Interaction Network
Click a node to explore
SLC12A3BSNDKLHL3WNK1SCNN1ASCNN1BSCNN1G
PROTEIN STRUCTURE
Preparing viewer…
PDB8FHQ Β· 2.81 Γ… Β· EM
View on RCSB β†—
Constraintβ“˜
LOEUFβ“˜
1.00LoF Tolerant
pLIβ“˜
0.00Tolerant
Observed/Expected LoF0.85 [0.72–1.00]
RankingsWhere SLC12A3 stands among ~20K protein-coding genes
  • #2,660of 20,598
    Most Researched168 Β· top quartile
  • #117of 1,025
    FDA-Approved Drug Targets13 Β· top quartile
  • #118of 5,498
    Most Pathogenic Variants454 Β· top 5%
  • #9,724of 17,882
    Most Constrained (LOEUF)1.00
Genes detectedSLC12A3
Sources retrieved25 papers
Response timeβ€”
πŸ“„ Sources
25β–Ό
1
Spectrum of mutations in Gitelman syndrome.
PMID: 21415153
J Am Soc Nephrol Β· 2011
1.00
2
Gitelman syndrome: consensus and guidance from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.
PMID: 28003083
Kidney Int Β· 2017
0.90
3
Genetic Analysis of SLC12A3 Gene in Chinese Patients with Gitelman Syndrome.
PMID: 31398183
Med Sci Monit Β· 2019
0.80
4
Novel NCC mutants and functional analysis in a new cohort of patients with Gitelman syndrome.
PMID: 22009145
Eur J Hum Genet Β· 2012
0.70
5
Genetic analysis of
PMID: 33993910
Clin Nephrol Β· 2021
0.64